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Management Program (CVDMP), King Abdulaziz Medi-
cal Centre and associated clinical characteristics.
Design and methodology: This retrospective,
descriptive study enrolled all adult patients with HF,
ejection fraction (EF) 640% and complete data attending
CVDMP from 2000 to 2011.
The World Health Organization’s definition of anemia
was used and data was extracted from patient’s files and
electronic database from the first visit.
Statistical analysis was performed using SPSS, version
18. Descriptive statistics were used to summarize patient
characteristics. Continuous data was compared using t-
test and presented as mean ± SD. Categorical data was
compared using correlation and Chi Square/Fisher exact
test and presented as frequencies.
Results: Mean age of patients (n = 1256) was
58.8 years (STD ± 12.5) with 74.5% male. At admission,
27% (337) of patients were anaemic, with higher preva-
lence in females (33.4%), P < 0.022. Clinical characteristics
included; 63% were P60 years, 74.7% were hypertensive
(P = <0.11), 77.4% had diabetes (P = <0.03) and 28.6% had
renal disease (P = < 0.00). Mean EF (30%), BP (120 mm Hg,
±20) and mean HR of 73 bpm (±11) were identical in both
groups. Worse symptoms was associated with anaemic
patients 8% (P = <0.00) and overall mortality was signifi-
cantly higher in the anaemic group 11.9% (P = <0.00).
Conclusion: Anaemia is highly prevalent in patients
with HF attending CVDMP, particularly, in the elderly
and in females. Anaemic patients had worse symptoms
and higher overall mortality than none anaemic.
http://dx.doi:10.1016/j.jsha.2012.06.208
The short and long term effect of Blalock–Taussig
shunt size on the outcome after first palliative
surgery
Raja Abou Elella, Neil Urmatam, Jack Kalloghian,
Mammdouh Alahmadi, Abdullah Alwadaai
Introduction: The Blalock–Taussig (BT) shunt is
regarded a safe, and effective means increasing pulmon-
ary blood flow for cyanotic heart conditions. Evaluation
of shunt size for postoperative hemodynamics and until
second stage palliation remains difficult.
Our objectives are to compare the effect of different
shunt size on short and long-term outcomes after BT
shunt.
Methods: All patients’ records with modified BT
shunt between January 2007–December 2010 were retro-
spectively reviewed. Patients were divided into two
groups: group A with BT shunt 3.5 mm, and group B with
BT shunt 4 mm. Groups were compared for primary out-
come: ICU course, ICU and hospital stay and secondary
outcome: branch pulmonary arteries size (PAs) before
second surgery.
Results: 29 (23%) patients were in group A, and 60
(67%) in group B. The mean age and weight for group
A was 3 ± 3 weeks and 2.9 ± 0.7 kg, while for group B
was 9 ± 8.6 weeks and 4 ± 2 kg P < 0.0005 and P < 0.002,
respectively. There was no significant difference between
the two groups in regards to diastolic blood pressure,
urine output and lactate during the first 48-h postopera-
tive. The mean ICU and hospital stay was 10.3 ± 8.9 days
and 17.8 ± 11.4 days for group A, 7.5 ± 6.3 days and
10.5 ± 6.3 days for group B with P < 0.22 and P < 0.21,
respectively. Yet group B had better branch PAs size
and require less intervention for branch PAs in compar-
ison to group A.
Conclusion: These data suggest that shunt size does
not affect the short-term outcome, but rather bigger
shunt size has led to better growth of branch PAs.
http://dx.doi:10.1016/j.jsha.2012.06.209
Riociguat for treatment of experimental right heart
hypertrophy
Ralph Theo Schermuly
Rationale: Right heart failure is a prevalent mecha-
nism of cardiovascular collapse and distinctly different
from left heart failure. Afterload reduction has been the
main focus to treat right ventricular (RV) dysfunction,
but it cannot be achieved in many cases. A new strategy
is to directly target increased RV hypertrophy. In this
study we assessed the effects of the sGC stimulator rio-
ciguat and the PDE5 inhibitor sildenafil on RV function
and RV hypertrophy.
Methods: Chronic pressure-overload RV hypertro-
phy was induced by pulmonary artery banding (PAB)
in male C57/Bl6 wild-type mice. Drug treatment was
started seven days after surgery for the duration of
2 weeks, after which RV morphology and function were
assessed using Magnetic Resonance Imaging (MRI) and
RV catheterization.
Results: Three weeks after PAB, placebo-treated
mice showed several signs of RV dysfunction as com-
pared to sham-operated mice. PAB led to RV systolic dys-
function, and treatment with sildenafil did neither lead to
significant changes in RV end-systolic volume, RV stroke
volume nor RV ejection fraction, while treatment with
riociguat led to significant improvement in RV end-
systolic volume, RV stroke volume and RV ejection
fraction. Drug treatment had no effects on either RV
hypertrophy or RV/(LV + S) ratio. However, histological
assessment of fibrosis showed that sildenafil had no
effects on the collagen content while riociguat signifi-
cantly decreased the amount of collagen.
Conclusion: Riociguat led to significant improve-
ments in RV function, accompanied by decreased fibrosis
and may thus offer for right heart specific treatment in
pulmonary vascular diseases.
http://dx.doi:10.1016/j.jsha.2012.06.210
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